Methods for treating cancer using an immuno-toxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer associated protease site cleaved by mmp-2 or mmp-9
AssigneeUniversity of Zurich
InventorsUwe Zangemeister-Wittke, Claudio De Paolo
Life of this patent
Estimating the term…
Abstract
The present invention provides a modified toxin having an ETA moiety that has the furin site replaced with a cancer-associated protease site. The present invention also provides modified immunotoxins having a ligand that binds to a cancer cell attached to an ETA moiety that has the furin site replaced with a cancer-associated protease site. Also provided are a method of inhibiting or destroying mammalian cancer cells using the immunotoxins of the invention and pharmaceutical compositions for treating human cancer.
Claims30
A toxin comprising an ETA moiety having a furin site replaced with a cancer-associated protease site.
An immunotoxin comprising
- (a) a ligand that binds to a cancer cell attached to;
- (b) a modified toxin comprising an ETA moiety having a
- furin site replaced with a cancer-associated protease site.
An immunotoxin comprising VB4-845 having a furin site replaced with a cancer-associated protease site.
17-20. (canceled)
A process for preparing a pharmaceutical for treating a mammal with cancer comprising
- (a) identifying a cleavage recognition site for a cancer-associated protease;
- (b) preparing an immunotoxin having a cancer-binding ligand attached to a modified toxin comprising an ETA moiety having a furin site replaced with the cleavage recognition site;
- and
- (c) suspending the protein in a pharmaceutically acceptable carrier, diluent or excipient.
A pharmaceutical composition comprising an immunotoxin having a cancer-binding ligand attached to a modified toxin comprising an ETA moiety having a furin site replaced by a cancer-associated protease site;
- and a pharmaceutically acceptable carrier, diluent or excipient.
Dependencies are inferred from the claim text.